# Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy

> **NCT04697186** · PHASE4 · COMPLETED · sponsor: **Xijing Hospital of Digestive Diseases** · enrollment: 524 (actual)

## Conditions studied

- Dyspepsia
- Chronic Gastritis
- Gastric Cancer
- Helicobacter Pylori Infection

## Interventions

- **DRUG:** Berberine
- **DRUG:** Amoxicillin
- **DRUG:** Rabeprazole
- **DRUG:** Amoxicillin
- **DRUG:** Clarithromycin
- **DRUG:** Rabeprazole
- **DRUG:** Bismuth

## Key facts

- **NCT ID:** NCT04697186
- **Lead sponsor:** Xijing Hospital of Digestive Diseases
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-07
- **Primary completion:** 2021-12-20
- **Final completion:** 2021-12-20
- **Target enrollment:** 524 (ACTUAL)
- **Last updated:** 2023-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04697186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04697186, "Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04697186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*